At its Meeting on 23 May 2022, the Transparency Council adopted Opinion No. 84/2022 on reimbursement of medicines containing the active substance rivastigminum for indications for use or posology or route of administration different from those specified in the Summary of Product Characteristics, i.e. dementia with Lewy bodies.
Publication with the minutes of the Transparency Council meeting